Coronavirus Pandemic – Service Status & News
In order to keep all our users informed of our current service status levels in light of the ongoing coronavirus pandemic, we will be updating the following on a daily basis.
Our service status level today (01/12/2020) is: 2
In other news, we are pleased to announce that following accreditation to ISO15189, our new NGS Multi-Gene Panel (MGP-4) is now fully live, and all preceding panels have now been withdrawn. From the 1st of June, any specimens received with old request forms for MGP-1, 2 or 3, will be processed using MGP-4, without further case by case notification. Any requests for MGP-1 or 2 received after this date will receive MGP-4 DNA. Similarly, any requests for MGP-3 will receive both MGP-4 DNA & RNA. MGP-4 RNA in isolation can only be ordered with a new request form, which can be downloaded from the ‘ORDER A TEST‘ page.
|1||Full service as normal:
All services available with normal turn round times expected.
|2||Full clinical service as normal:
Contract research/projects & R&D may be reduced or suspended, but clinical services are unaffected.
|3||Minor disruption to clinical service:
Increased turn round times or temporary suspension of lower priority services e.g. Lynch syndrome pre-screening (MLH1 promoter methylation) and ‘batched’ (i.e. non-rapid) BRAF testing. All other clinical services as normal.
|4||Moderate disruption to clinical service:
Increased turn round times or temporary suspension of moderate priority services e.g. Endopredict and NGS based analyses. Skeleton service overall, but all cases still being accepted, processed and reported for key markers only as quickly as possible.
|5||Major disruption to clinical service:
Processing of the highest priority cases for key markers only. All other samples will be stored for subsequent processing at the earliest possible time. Telephone calls may not be answered, with only the highest priority emails receiving responses.
We are very sorry, but the service is currently closed and cannot accept deliveries, please do not send further specimens until otherwise notified. We estimate that this situation is likely to continue until: dd/mm/yyyy
We help patients with cancer find the right treatment or clinical trial.
We offer a number of tests to help clinicians understand which approved anti-cancer treatments should be most effective for their patients.
Our tests can also direct patients to off-label treatments and clinical trials, thus providing additional options if standard therapies are not suitable.
We can also help identify treatments that won’t work, thus reducing costs and the risk of any adverse reactions associated with their use.
What tests do you offer?
Next Generation Sequencing (NGS) based
Although we offer a full range of services in order to best fit the varied needs of customers, our core test utilises NGS technology. This allows us to examine multiple genes simultaneously, thus gaining a better understanding of what may, or alternatively may not, be driving a patient’s cancer. This in turn gives the clinical care team a better chance of finding something that can help fight it.
Our current principal NGS test (MGP-4) is comprised of two components (click here for a general overview and here for specific details of exactly what is included) which have been developed and validated in-house (we are UKAS Accredited to ISO15189). One if these components sequences DNA isolated from the tumour, the other RNA, and collectively they are designed to help guide treatment decisions with specific targeted therapies (excludes PARP or immune Check Point inhibitors). For less common tumour types and/or those where targetable variants/processes may exist in genes beyond those included in our in-house NGS test, we can also facilitate pre-analytical assessment and specimen referrals on to our carefully selected partner organisations.
In additional to NGS based tests we also offer a range of other molecular diagnostic assays providing diagnostic, prognostic and treatment stratification related information. These include:
- Rapid single gene (BRAF, KRAS, NRAS & EGFR) analyses, for use in time-critical solid tumour cases.
- Endopredict (from Myriad Genetics), for use in breast cancer patients to assess the relative risks/benefits of post surgical chemotherapy.
- Micro-Satellite Instability (MSI) analysis, for use in assessing the likelihood of Lynch Syndrome and/or potential response to immune Check Point Inhibitor (CPI) therapy in certain tumours.
- MLH1 promoter methylation anaylsis, for use in conjunction with MSI, BRAF and/or immunohistochemistry to assess the likelihood of Lynch Syndrome.
As we are constantly developing and validating new tests to support and expand the existing repertoire, make sure you watch this space!
When might I refer a patient?
Our NGS based test is ideal for patients with common solid tumours such lung, colorectal, skin, gastric and breast cancers. You can use our tests for patients who have just been diagnosed, to make sure they get the correct approved treatment from the word go. Alternatively, you can order for patients with more advanced disease, who have perhaps exhausted their standard care options. The latter allowing further ‘off-label’ or clinical trial opportunities to be explored.
Find out more about what our tests can tell you.
Why choose SCMD?
Launched in 2014, we were one of the first labs in the UK to start routine tumour profiling (i.e. for all cases by default) by NGS, and as a result have an extraordinary range of experience and expertise within our team. We have always stayed focused on clinically actionable targets making sure that our tests are as sensitive and robust as possible, meaning that we can successfully analyse very small low tumour content samples, with which many of our competitors may struggle.
Our laboratory is a partnership between:
HCA’s global Cancer Institute. Its research arm not only focuses on advancing therapies for patients, but is one of the world’s leading clinical research organisations conducting clinical trials. Sarah Cannon has been a clinical trial leader in the majority of cancer therapies over the last 10 years.